ClinicalTrials.gg
Not yet recruitingNCT05833204BARDUpdated Apr 29, 2026

BARBED vs. STANDARD Suture for Colporrhaphy at the End of Laparoscopic Hysterectomy

An interventional study of Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture and Laparoscopic colporrhaphy with standard 0-caliber absorbable suture in Vaginal Cuff Complications, sponsored by Universita di Verona. Not yet recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Universita di Verona · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,614
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Hysterectomy is one of the most common surgical procedures performed worldwide, with more than 400,000 hysterectomies performed annually in the United States. As a consequence, even uncommon complications can affect large numbers of patients. Among potentially life-threatening events, vaginal cuff dehiscence complicates 0.14-1.38% of procedures, and any vaginal cuff complications (dehiscence, hematoma, bleeding, infection) are estimated to affect 4.7-9.8% of patients. In this scenario, any preventive strategy can provide clinically relevant benefits. Regarding colporrhaphy, only the adoption of a laparoscopic approach instead of a vaginal approach is supported by high-quality evidence. Our group demonstrated that the laparoscopic closure of the vaginal cuff after total laparoscopic hysterectomy reduces the incidence of vaginal cuff complications.

Among other potentially effective interventions, the use of barbed sutures was associated with a lower incidence of vaginal cuff dehiscence than the standard suture. In a recent meta-analysis, the use of barbed sutures has been associated with a pooled incidence of vaginal cuff dehiscence of 0.4% versus 2% after a traditional vaginal suture. However, this evidence is limited because most pooled studies were retrospective, and only two were randomized controlled trials. Moreover, these two randomized controlled trials had a very small sample size and were not powered to detect clinically relevant differences. On that basis, despite the promising utility of barbed sutures for vaginal cuff closure after total laparoscopic hysterectomy, the choice of the type of suture is not evidence-based but still guided by personal opinions, as well as by the preference and habits of the operators.

Therefore, this study aims to investigate whether the laparoscopic vaginal cuff closure with barbed suture determines a lower incidence of vaginal cuff dehiscence and complications than conventional sutures after total laparoscopic hysterectomy.

02

Conditions studied

  • Vaginal Cuff Complications

Keywords

  • Laparoscopy
  • Hysterectomy
  • Vaginal cuff closure
  • Barbed sutures
  • Vaginal cuff complications
  • Vaginal cuff dehiscence
03

In context

Lead sponsor

Universita di Verona is the lead sponsor of 125 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective total laparoscopic hysterectomy
  • Surgery performed for the treatment of benign pathology
  • Age > 18 years
  • Surgery performed by laparoscopy
  • Signature of

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing emergent surgery
  • Patients candidates for hysterectomy for oncological indication
  • Patients who underwent previous radiation therapy
  • Patients allergic to the suture material used in the study
  • Patients unable to express adequate to participate in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,614 participants (estimated)

Study arms

  • Experimental
    Colporrhaphy with barbed absorbable suture

    The colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)

    Procedure: Laparoscopic colporrhaphy with 0-caliber barbed absorbable suture

  • Active comparator
    Colporrhaphy with standard absorbable suture

    The colporrhaphy will be performed using a standard 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)

    Procedure: Laparoscopic colporrhaphy with standard 0-caliber absorbable suture

Interventions

  • ProcedureLaparoscopic colporrhaphy with 0-caliber barbed absorbable suture

    After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber barbed absorbable suture (V-Loc ™, Covidien, Medtronic)

  • ProcedureLaparoscopic colporrhaphy with standard 0-caliber absorbable suture

    After the total laparoscopic hysterectomy, the colporrhaphy will be performed using a 0-caliber absorbable suture made of a coated braided thread (Vicryl; Ethicon Inc, Sommerville, NJ)

06

What researchers measure

Primary outcomes

  1. Vaginal cuff dehiscence

    Any partial or total separation of the vaginal cuff

    Time frame: 30 days after surgery

  2. Vaginal cuff dehiscence

    Any partial or total separation of the vaginal cuff

    Time frame: 90 days after surgery

Secondary outcomes

  1. Vaginal cuff complications

    Hematoma, abscess, infections, bleeding, resuture of the vaginal cuff

    Time frame: 30 days after surgery

  2. Vaginal cuff complications

    Hematoma, abscess, infections, bleeding, resuture of the vaginal cuff

    Time frame: 90 days after surgery

  3. Hospital stay

    Days of hospitalization from the day of admission to the day of discharge.

    Time frame: From the date of hospital admission to the date of hospital discharge.

  4. Operative time

    Time between first incision and skin closure

    Time frame: During surgery

  5. Intraoperative blood loss

    Total blood aspirate during the surgical procedure

    Time frame: During surgery

  6. 30-day post-surgical morbidity

    Perioperative (intraoperative and postoperative) complications graded based on the Clavien-Dindo classification

    Time frame: 30 days after surgery

  7. Quality of life index

    The Short Form 12 Health Survey (SF-12) investigates 8 different health aspects. Physical activity, role and physical health, role and emotional state, and mental health are measured by two questions. The SF-12 scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: 90 days after surgery

  8. Sexual function

    The female sexual function index (FSFI) consists of 19 multiple-choice items that assess female sexual functioning based on 6 domains: desire, arousal, orgasm, pain, sexual satisfaction, and lubrication. The total score ranges from 0 to 36, with 26.55 as the cut-off suggesting the presence of sexual dysfunction. The higher the score, the better the sexual function.

    Time frame: 90 days after surgery

07

Study locations

1 site
08

References and documents

Publications

  • Uccella S, Zorzato PC, Kho RM. Incidence and Prevention of Vaginal Cuff Dehiscence after Laparoscopic and Robotic Hysterectomy: A Systematic Review and Meta-analysis. J Minim Invasive Gynecol. 2021 Mar;28(3):710-720. doi: 10.1016/j.jmig.2020.12.016. Epub 2021 Jan 5. PubMed 33348012 ↗
  • Uccella S, Malzoni M, Cromi A, Seracchioli R, Ciravolo G, Fanfani F, Shakir F, Gueli Alletti S, Legge F, Berretta R, Corrado G, Casarella L, Donarini P, Zanello M, Perrone E, Gisone B, Vizza E, Scambia G, Ghezzi F. Laparoscopic vs transvaginal cuff closure after total laparoscopic hysterectomy: a randomized trial by the Italian Society of Gynecologic Endoscopy. Am J Obstet Gynecol. 2018 May;218(5):500.e1-500.e13. doi: 10.1016/j.ajog.2018.01.029. Epub 2018 Feb 2. PubMed 29410107 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2028, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2023
First posted
Apr 27, 2023
StartEst.
Sep 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05833204
Responsible party
Stefano Uccella (Associate Professor, Universita di Verona) — Principal investigator
First posted
Apr 27, 2023
Start date
Sep 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Stefano Uccella, MD, PhD
Contact
stefano.uccella@univr.it
0039 045 812 2720
Simone Garzon, MD
Contact
simone.garzon@univr.it
0039 045 812 2720
Stefano Uccella, MD, PhD
principal investigator · Universita di Verona
Simone Garzon, MD
principal investigator · Universita di Verona
Pier Carlo Zorzato, MD
principal investigator · Universita di Verona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion